Solventum Corporation Stock Price, News & Analysis

Solventum (NYSE:SOLV) has launched tender offers to purchase up to $1.75 billion of its outstanding notes. The offers are divided into two pools: Pool 1 with a maximum purchase amount of $1.25 billion covering four series of notes, and Pool 2 with a maximum of $500 million covering two series of notes.

Holders who tender their notes by the Early Tender Date of September 5, 2025, will receive the Total Consideration, which includes an Early Tender Payment of $30 per $1,000 principal amount. The tender offers will expire on September 22, 2025. The Early Settlement Date is expected around September 10, 2025, with the Final Settlement Date around September 25, 2025.

Solventum Corporation (NYSE: SOLV) has announced the pricing of a secondary offering of 8.8 million shares of common stock, which is expected to generate approximately $648 million in gross proceeds for 3M Company, the selling shareholder.

The offering, expected to close around August 15, 2025, is being managed by Goldman Sachs & Co. LLC and BofA Securities. Importantly, Solventum will not receive any proceeds from this transaction as all shares are being sold by 3M Company. The offering is being made through the company's shelf registration statement that became effective on August 13, 2025.

Solventum Corporation (NYSE: SOLV) has announced a secondary offering of 8,800,000 shares of its common stock, which will be sold entirely by 3M Company (the Selling Shareholder). The offering will be managed by Goldman Sachs & Co. LLC and BofA Securities, Inc. as underwriters.

The shares are being offered through Solventum's shelf registration statement on Form S-3, which became effective on August 13, 2025. Importantly, Solventum will not receive any proceeds from this offering as all shares are being sold by 3M Company. The offering will be conducted through a preliminary prospectus supplement and accompanying prospectus filed with the SEC.

Solventum (NYSE: SOLV) reported Q2 2025 financial results with sales increasing 3.9% to $2.2 billion and organic sales growth of 2.8%. The company achieved GAAP diluted EPS of $0.51 and adjusted diluted EPS of $1.69, marking five consecutive quarters of positive sales volume growth since implementing its transformation strategy.

Key financial metrics include operating cash flow of $169 million and free cash flow of $59 million. The company has increased its full-year 2025 guidance, projecting organic sales growth of 2.0% to 3.0% and adjusted EPS of $5.80 to $5.95. All segments showed positive organic growth, primarily driven by MedSurg and HIS segments.

Solventum (NYSE: SOLV) has scheduled its second quarter fiscal 2025 earnings release for Thursday, August 7, 2025, after U.S. market close. The company will host a webcast at 3:30 p.m. CDT / 4:30 p.m. EDT to discuss financial results and business updates.

Investors can access the webcast through the company's investor relations website at investors.solventum.com. The event will be available via phone with U.S. dial-in at +1 (800) 715-9871 and international dial-in at +1 (646) 307-1963, using Conference ID 6342275.

Following the event, a replay of the webcast, earnings release, presentation slides, and supplemental financial information will be accessible on Solventum's Investor Relations website.

Solventum (NYSE: SOLV) has been recognized by U.S. News & World Report as one of the 2025-2026 Best Companies to Work For, achieving top rankings in multiple categories just 14 months after its formation. The company ranked in the top 25% for healthcare and research companies and top 25% of Midwest companies. Solventum received perfect 5/5 scores in Work-Life Balance, Stability, and Belongingness categories. The recognition marks a successful milestone in phase one of Solventum's three-phased transformation plan, which focuses on culture and business stabilization. U.S. News evaluated over 5,000 public companies using factors including pay, benefits, work-life balance, comfort, belonging, job stability, and career opportunities.

Solventum (NYSE: SOLV) has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference, scheduled for June 10, 2025, in Miami, FL. Company executives will engage in a fireside chat starting at 4:00 p.m. EDT. Interested parties can access both live and archived versions of the discussion through the investor relations section of Solventum's website at investors.solventum.com.

Solventum (NYSE: SOLV) has announced its participation in the 2025 BofA Securities Health Care Conference. Company executives will engage in a fireside chat on Tuesday, May 13, 2025, at 2:20 p.m. PST in Las Vegas, NV. Investors and interested parties can access both live and archived replays of the presentation through the company's investor relations website at investors.solventum.com.

Solventum (NYSE: SOLV) reported its Q1 2025 financial results with sales increasing 2.6% to $2.1 billion, showing 4.3% organic growth. The company reported GAAP diluted EPS of $0.78 and adjusted EPS of $1.34. Operating cash flow was $29 million with negative free cash flow of $80 million. Performance was marked by revenue growth across segments, particularly in MedSurg and HIS, but saw declining margins due to supply agreement costs and increased operating expenses. The company increased its full-year 2025 organic sales growth guidance to +1.5% to +2.5% (from previous +1.0% to +2.0%), while maintaining adjusted EPS guidance of $5.45-$5.65 and free cash flow guidance of $450M-$550M. The company is executing a 3-phased transformation while managing through macro trends and short-term pressures.